Project Grant K08HL175118
Award Date 9/15/25
Completion Date 6/30/30
Dollars Obligated $164K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Portland, OR 97239, USA
Similar Awards
- This $457,514 Project Grant award was provided by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to Thomas Jefferson University, doing business as Sidney Kimmel Medical College. The grant funding supports research to investigate the role of platelet activation in maintaining hemostasis and reducing bleeding in coagulation disorders. The proposed studies will explore mechanisms by which reduced thrombin production limits platelet-mediated hemostatic...
- This Project Grant award of $636,982.00 was provided by the National Heart, Lung, and Blood Institute under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The grant supports research to comprehensively investigate the proteolytic mechanisms that govern factor VIII regulation before and after activation, which is critical for maintaining normal blood clotting and preventing bleeding disorders like hemophilia A. The project aims to understand how proteolysis of factor...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $639,165 project grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Washington University to develop an equitable and accessible wearable device for continuous calculation of blood loss for postpartum hemorrhage (PPH). PPH is the leading cause of maternal mortality worldwide, with disturbing racial disparities in the U.S. The research aims to create a non-invasive, light-based sensor system that can...
- This $601,169 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to better understand the molecular pathogenesis of myeloproliferative neoplasms (MPNs) and identify new therapeutic targets. Key focus areas include investigating the role of the PTPN1 tumor suppressor gene in MPN progression and the aberrant expression of TIMP-1 in MPN/myelofibrosis. The research is being conducted by the Rector & Visitors...
- This Project Grant award of $234,750.00 from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to examine the immunological mechanisms that initiate and orchestrate the development of anti-factor VIII alloantibodies, known as inhibitors, in patients with severe hemophilia A. The research is being conducted by Emory University and seeks to identify key immune pathways and risk factors that predict the likelihood of inhibitor development, with the goal...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $178,068 to support a 4-year research plan led by Dr. Susanna Mitro at Kaiser Foundation Hospitals. The project aims to clarify associations between blood pressure, antihypertensive medication use, and uterine fibroid diagnosis, as well as to test renin-angiotensin system signaling as a potential mechanism linking blood pressure and fibroid development. Key...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $249,000.00 to Oakland University to conduct research on the pre-mRNA processing and function of alternatively spliced isoforms of Tissue Factor Pathway Inhibitor (TFPI), a vital factor in the balance of hemostasis between pro- and anticoagulant factors. The research aims to differentiate the physiological, site-specific production of each TFPI isoform...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) aims to investigate the role of platelet ABO(H) blood group antigens in hemostasis and thrombosis. The $445,708 award to Brigham & Women's Hospital, a subsidiary of Partners Healthcare System, will fund a 3-year research project to: 1) define the impact of ABO(H) glycans on platelet binding to von Willebrand factor, and 2) identify ABO(H) antigen-carrying glycoproteins...
- The National Heart Lung and Blood Institute awarded a $503,637 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The University of Kentucky Research Foundation. This grant, awarded on January 15, 2025, supports research to investigate the mechanisms of thrombosis (blood clots) in patients with COVID-19 infection. The key objectives are to measure changes in the hemostatic (clotting) and fibrinolytic (clot-dissolving) systems in COVID-19 patients from initial...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $1,276,908 in funding to Bloodworks, a non-profit organization based in Seattle, Washington. The award, effective March 1, 2025 through February 28, 2032, supports molecular and translational research studies focused on hematological disorders, specifically von Willebrand disease and sickle cell disease. The research aims to...